Dr. William Ivanova

Radiation oncologist · Gustave Roussy · France (FR) · Oncology

Tier 1STK-0027GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: NSCLC, SCLC
Scientific interests: irAE management
Engagement preference: Either
Advisory boards: 1
Publications: 112
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 1: 4 per year (assumption)

Last engaged: 30 Jun 2026 (77 days ago)
Next planned contact: 29 Sept 2026
Last 6 months vs target: 100%
2 of 2 expected engagements

Insights from this stakeholder (1)

INS-0040Chemotherapy-free first line
31 Mar 2026 · Efficacy
MediumClosed

Engagement history (2)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
30 Jun 2026	Scientific exchange	Virtual	James Whitfield	Vantrexa	Comparator checkpoint monotherapy	0	—	Reviewed	ENG-0108
31 Mar 2026	Congress meeting	In person	James Whitfield	Vantrexa	Chemotherapy-free first line	1	Compliance	Reviewed	ENG-0051

Timeline

30 Jun 2026
Scientific exchange
Comparator checkpoint monotherapy
31 Mar 2026
Congress meeting
Chemotherapy-free first line

Related stakeholders (5)

Gustave Roussy

Dr. Hiroshi Zimmermann
Radiation oncologist
Tier 1
Dr. Chloé Xu
Oncology pharmacist
Tier 2
Dr. Ulrich Kimura
Oncology pharmacist
Tier 1
Dr. Yuki Castellano
Academic nephrologist
Tier 3
Dr. Javier Kimura
Renal pathologist
Tier 3